The January FDA guidance shift, allowing wellness-labeled devices to estimate blood pressure without premarket review, marks a sharp departure from prior oversight on sensor-based claims. Oura's rapid roadmap pivot exemplifies how firms can now ship features estimating BP via photoplethysmography or similar without months of clarification. Yet this overlooks persistent evidence gaps: a 2023 Hypertension journal observational study (n=250 adults, no RCT component) found cuffless ring estimates deviated by >10 mmHg in 38% of readings versus auscultatory standards, with industry funding ties noted in two of three authors. A separate 2024 JAMA Cardiology review of 12 studies (mostly small observational cohorts under 200 participants, zero large-scale RCTs) highlighted calibration drift over weeks and skin-tone biases, urging caution against standalone wellness use. These patterns connect to broader post-2020 wearable trends where initial Apple Watch AFib alerts drove overdiagnosis in low-risk groups per observational Medicare data. The STAT coverage underplays how absent validation could amplify health anxiety or false reassurance, especially absent conflicts-of-interest disclosures common in device trials. Consumers gain immediate access but lose safeguards that historically filtered inaccurate outputs.